
BIOA Stock Forecast & Price Target
BIOA Analyst Ratings
Bulls say
Bioage Labs is attractive because BGE-102 targets NLRP3, an upstream inflammatory node that may offer broader and more durable disease control than distal cytokine blockade, while Phase 1 data already showed about a 90% reduction in IL-1β and an 80% to 90% reduction in hsCRP. Its lead program has multiple near-term catalysts, with QUELL-CV enrollment completed and topline expected in 4Q26, plus QUELL-DME now using a 180-patient, three-arm design with BCVA as the primary endpoint and topline expected in 2H27. Financially, the company reported $352.3 million in cash, cash equivalents, and marketable securities as of September 30, 2026, supporting a runway through 2029 and reducing near-term dilution risk while the data story develops.
Bears say
Bioage Labs is burdened by widening losses, with 3Q26 net loss rising to $33.5 million from $20.2 million in 3Q25 as R&D climbed to $30.2 million, reflecting heavier BGE-102 spending and still-limited collaboration revenue of just $0.3 million. Its lead programs face demanding clinical and regulatory hurdles: QUELL-CV is only now in a 160-patient, 12-week cardiovascular study, QUELL-DME is a harder 180-patient visual-acuity trial against anti-VEGF control, and no NLRP3 inhibitor has been approved while hsCRP remains an unproven surrogate. The stock also carries meaningful dilution and valuation risk, with $381.3 million in cash at June 30, 2026 but a modeled need to raise $200 million in FY27E, while competition from better-capitalized peers and a valuation tied entirely to explicit FY27E to FY45E forecasts limit downside protection.
This aggregate rating is based on analysts' research of BioAge Labs Inc. and is not a guaranteed prediction by Public.com or investment advice.
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BioAge Labs Inc. (BIOA) Forecast
BIOA Analyst Forecast & Price Prediction
Start investing in BIOA
Order type
Buy in
Order amount
Est. shares
0 shares